Prevalence of (HCV) which represent From 5 to 7% of total population in low middle income countries like Egypt. Hepatocellular carcinoma is one of major complications of HCV infection At Africa for example Egypt is accounting for approximately half of the data related to HCC .Over the last two decades, a substantial increase (from 4.0% to 7.2%) with HCC in the proportion of chronic liver disease Egyptian patients was observed.The main objective behind conducting this study was to conduct an economic evaluation of Sorafenib as a pioneer molecule of innovative medicines for the treatment of hepatocellular carcinoma at law and middle income countries taking Egypt as a first country in those serious of evaluations due to representing sample of Egypt at (HCV,HBV, HCC) incidence and prevalence plus nature of it is experience compared to other countries over a time horizon of 4 years. For maximizing health gain of the patients while ensuring the most efficient utilization of the finite resources available to the Egyptian Ministry of Health.
